Form 8-K - Current report:
SEC Accession No. 0001835268-25-000013
Filing Date
2025-03-31
Accepted
2025-03-31 09:02:18
Documents
15
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cntb-20250331.htm   iXBRL 8-K 29751
2 EX-99.1 cntbpressreleaseyear-endre.htm EX-99.1 45349
  Complete submission text file 0001835268-25-000013.txt   246442

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntb-20250331.xsd EX-101.SCH 2060
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cntb-20250331_def.xml EX-101.DEF 15471
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntb-20250331_lab.xml EX-101.LAB 26912
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntb-20250331_pre.xml EX-101.PRE 16173
18 EXTRACTED XBRL INSTANCE DOCUMENT cntb-20250331_htm.xml XML 3915
Mailing Address 3580 CARMEL MOUNTAIN ROAD, SUITE 200 SAN DIEGO CA 92130
Business Address 3580 CARMEL MOUNTAIN ROAD, SUITE 200 SAN DIEGO CA 92130 858-727-1040
Connect Biopharma Holdings Ltd (Filer) CIK: 0001835268 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40212 | Film No.: 25789173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)